Full-Time

IT Transformation Solution Lead

Posted on 5/9/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

London, UK + 1 more

More locations: Woking, UK

Hybrid

Hybrid role; 50% office, 50% remote; must be within commuting distance of London or Woking office.

Category
IT & Security (1)
Required Skills
Microsoft Azure
Agile
SAP Products
JIRA
SCRUM
REST APIs
Confluence
Oracle
Data Analysis
Requirements
  • Minimum of 10 years' experience as a Solutions Lead, Solutions Architect, or equivalent role, with substantial experience in integrated supply chain technology solutions.
  • Demonstrable, hands-on experience deploying or championing AI, intelligent automation, generative AI, or other accelerant technologies within solution design and delivery — not just awareness, but practical application with measurable outcomes.
  • Proven track record of operating in complex, matrixed organisations, delivering integrated solutions across multiple stakeholders, functions, and geographies.
  • Deep expertise in ERP and/or WMS platforms (e.g., SAP, Oracle, Manhattan, Blue Yonder) with experience in integration architecture and data flows.
  • Strong experience with Cloud/SaaS adoption strategies, API-first design, and modern application architecture patterns.
  • Demonstrable ability to build and maintain strong stakeholder relationships at all levels, influencing without authority in politically complex environments.
  • Experience with Agile delivery methodologies (Scrum, SAFe, Kanban) and modern delivery tooling (JIRA, Azure DevOps, Confluence).
  • Excellent communication skills — ability to translate complex technical concepts into clear business language for senior stakeholders.
  • Experience working across multiple geographies or diverse, culturally varied stakeholder bases.
  • Bachelor's degree in Computer Science, Information Systems, Supply Chain Management, Engineering, or a related discipline (or equivalent experience).
  • Core Competencies include Strategic Thinking & Innovation; AI & Accelerant Mindset; Matrix Leadership & Influence; Communication & Stakeholder Management; Analytical Rigour & Problem-Solving; Adaptability & Resilience; Results Orientation.
Responsibilities
  • Champion the use of AI, generative AI (LLMs, AI assistants), and intelligent automation tools across the entire solutions lifecycle — from requirements gathering and design through to testing, deployment, and monitoring.
  • Identify and evaluate emerging accelerant technologies (AI-assisted code generation, automated testing frameworks, process mining, digital twins, AIOps) and drive their adoption within delivery teams to compress timelines and improve quality.
  • Define and implement AI-augmented design patterns that leverage machine learning for demand forecasting, anomaly detection, intelligent routing, and predictive maintenance within ERP/WMS ecosystems.
  • Lead proof-of-concept (PoC) initiatives to validate new AI and automation technologies against real business challenges, building business cases with clear ROI and benefits realisation frameworks.
  • Drive adoption of low-code/no-code platforms (e.g., Power Apps, Power Automate, Mendix) to empower business teams with self-service capabilities and accelerate solution delivery.
  • Establish and maintain an innovation pipeline of AI and accelerant technology opportunities, prioritised by strategic value, feasibility, and speed to impact.
  • Embed AI-driven efficiency practices into governance and delivery methodologies — ensuring AI is not a bolt-on but a core part of how the team operates.
  • Lead end-to-end integrated solutions design, working in partnership with Business Process Leads, IT Business Analysts, and the Solutions Director to define a comprehensive technology stack supporting Cencora's 3PL strategy.
  • Define application design patterns that support current and future commercial requirements, including integration architecture, data flows, API strategy, and non-functional requirements (performance, scalability, security, resilience).
  • Ensure full alignment and conformance with Cencora corporate technology standards, ISO policies, and technology approval processes.
  • Work with Cencora EIC teams to drive Cloud/SaaS adoption, defining migration strategies and cloud-native design principles.
  • Collaborate with Cencora ISO teams to complete vulnerability mitigation strategies and ensure cybersecurity best practice is embedded in all solution designs.
  • Bring industry-leading thinking on ERP, WMS, and supply chain technology platforms to solution design, ensuring Cencora remains at the forefront of capability.
  • Operate effectively within a complex, matrixed organisational structure — influencing and aligning stakeholders across IT, operations, commercial, compliance, and external partners without direct authority.
  • Build and sustain strong, trust-based relationships with stakeholders at all levels, from operational teams through to senior leadership and C-suite sponsors across multiple geographies.
  • Act as the primary solutions liaison between business process owners, IT delivery teams, corporate architecture, information security, and third-party vendors.
  • Navigate competing priorities, divergent requirements, and political complexity with diplomacy and commercial awareness, ensuring consensus-driven outcomes.
  • Lead cross-functional workshops, design reviews, steering committees, and governance forums, ensuring all voices are heard and decisions are well-documented.
  • Proactively manage stakeholder expectations through transparent communication, regular status updates, and early escalation of risks and issues.
  • Lead execution delivery through robust governance structures, Agile working methodologies, and the central use of AI technology to create efficiencies.
  • Drive a business-focused deployment, release management, and production readiness strategy aligned with client and commercial requirements.
  • Support vendor assessments and selection decisions in collaboration with VMO teams, ensuring comprehensive TPRM assessments are completed.
  • Deliver high-quality engineering practices including code reviews, testing strategy, environment management, and CI/CD pipeline design.
  • Monitor and report on project and programme progress in conjunction with relevant portfolio and project managers, ensuring risks and issues are properly raised and mitigated.
  • Define data strategies and integration approaches that enable AI/ML model development, real-time analytics, and operational intelligence across 3PL platforms.
  • Champion a data-driven culture, ensuring decisions are supported by evidence and insight, not assumption.
  • Bring industry trends, best practices, and latest strategic thinking related to ERP, WMS, AI, and supply chain technologies to ongoing programmes of work.
  • Continuously evaluate and improve delivery practices, tooling, and methodologies to increase velocity and quality.
Desired Qualifications
  • Experience in pharmaceutical, healthcare, or other regulated supply chain environments (desirable but not essential — strong supply chain/3PL technology experience in other sectors will be valued).
  • Experience with AI-assisted development tools (GitHub Copilot, Amazon CodeWhisperer, Azure AI), automated testing frameworks, or AIOps platforms.
  • Familiarity with process mining tools (Celonis, UiPath Process Mining) and digital twin modelling.
  • Experience with RPA tools (UiPath, Automation Anywhere, Power Automate) in logistics or supply chain workflows.
  • Knowledge of serialisation, track-and-trace, cold-chain logistics, or controlled substance handling.
  • TOGAF, AWS Solutions Architect, Azure Solutions Architect, or equivalent architecture certification.
  • Lean Six Sigma certification (Green Belt or above).
  • Experience with data visualisation platforms (Power BI, Tableau) and data engineering concepts (ETL, data modelling).
  • Understanding of GDP, GxP, DSCSA, or similar regulatory frameworks.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cencora who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.